Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice.

The Journal of antimicrobial chemotherapy ·Vol. 19 ·No. 5 ·1987-05-00 ·Pages 663-70

Troke PF, Andrews RJ, Marriott MS, Richardson K

Abstract

The efficacy of fluconazole, a new bis-triazole antifungal agent, was compared with that of orally administered ketoconazole and parenterally administered amphotericin B against aspergillus and cryptococcus infections in mice. Fluconazole was 5-20-fold more active than ketoconazole against systemic aspergillosis and against systemic, intracranial and pulmonary cryptococcosis but was less active than amphotericin B.

MeSH Terms

Amphotericin B/therapeutic use Animals Antifungal Agents/therapeutic use Aspergillosis/drug therapy Aspergillus flavus/drug effects Aspergillus fumigatus/drug effects Brain Diseases/drug therapy Cryptococcosis/drug therapy Female Fluconazole Ketoconazole/therapeutic use Lung Diseases, Fungal/drug therapy Mice Opportunistic Infections/drug therapy Triazoles/therapeutic use

Chemicals

Antifungal Agents Triazoles Amphotericin B Fluconazole Ketoconazole

Authors & Affiliations

4 authors, click to expand affiliations / ORCID

Troke P F

Andrews R J

Marriott M S

Richardson K

Article Info

Journal

The Journal of antimicrobial chemotherapy

Abbr.

J Antimicrob Chemother

ISSN

0305-7453

DOI

10.1093/jac/19.5.663

Published

1987-05-00

Pages

663-70

Language

English

Region

England

NLM ID

7513617

Subset

External Links

PubMed source DOI: 10.1093/jac/19.5.663 View journal details

Analysis Services

Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice.

Contact

WeChat Official Account